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ILLUSTRATIVE CASE
A 35-year-old woman comes to your offi ce 
with a headache that has persisted for 24 
hours—the typical duration of her migraines, 
she says. She is nauseated, photophobic, 
and has a right-sided headache that she 
rates as moderate to severe. You’ve read 
about the potential role of corticosteroids in 
treating acute migraine and wonder whether 
to add dexamethasone (Decadron) to the 
standard treatment. 
Migraine headaches present a therapeutic challenge: You need to determine which therapeutic 
regimen is best, not only for immediate 
relief, but also for its ability to prevent 
recurrence. With up to two-thirds of 
migraine patients experiencing another 
headache within 24 to 48 hours of treat-
ment,1 many seek repeat treatment with-
in a short time frame.2 As such, they’re at 
risk for medication overuse, which may 
contribute to an increase in both the in-
tensity and frequency of symptoms.3
❚  A steroid may blunt 
inﬂ ammatory response
The pathogenesis of migraine headache 
is poorly understood. One theory is that 
migraines are associated with a neuro-
genic infl ammatory response with the 
release of vasoactive neuropeptide. This 
infl ammation is thought to be respon-
sible for the initiation and perpetuation 
of the headache.1 It therefore follows 
that the addition of a steroid to stan-
dard migraine therapy may blunt this 
infl ammatory response. Several small 
studies have investigated this possibility, 
but they had inadequate power to de-
tect a meaningful difference. The meta-
analysis detailed in this PURL makes a 
stronger case.
Add dexamethasone to 
the standard treatment of 
moderate to severe migraine 
headache; a single dose 
(8-24 mg) may prevent short-
term recurrence, resulting in 
less need for medication and 
fewer repeat visits to the offi ce 
or emergency department.1
Strength of recommendation: 
A: A meta-analysis
Singh A, Alter HJ, Zaia B. Does the addition of 
dexamethasone to standard therapy for acute 
migraine headache decrease the incidence of 
recurrent headache for patients treated in the 
emergency department? A meta-analysis and sys-
tematic review of the literature. Acad Emerg Med. 
2008;15:1223-1233.
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This study was selected and 
evaluated using FPIN’s Priority 
Updates from the Research 
Literature (PURL) Surveillance 
System methodology. The 
criteria and ﬁ ndings leading to 
the selection of this study as 
a PURL can be accessed at 
www.jfponline.com/purls. 
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STUDY SUMMARY
❚  Only 1 steroid studied,
but it delivered 
Singh and colleagues performed a sys-
tematic search for randomized controlled 
trials (RCTs) studying the use of corti-
costeroids in the emergency department 
(ED) as a treatment adjunct for migraine 
headache.1 They used rigorous search 
methods and well-defi ned inclusion crite-
ria. The primary outcome of interest was 
the proportion of migraine patients who 
reported symptoms of moderate or severe 
headache at 24- to 72-hour follow-up. 
Seven studies, with a total of 742 
patients, met the inclusion criteria. All 
were RCTs in which participants and 
providers were blinded to treatment as-
signments, and all involved the addition 
of dexamethasone. No studies evaluating 
other steroids were found in the literature 
review. The patients were all diagnosed 
as having acute migraine headache by 
the ED physician, based on International 
Headache Society criteria.4 
 The adjunctive therapy—dexa-
methasone or placebo—was initiated in 
the ED, in addition to routine treatment. 
The standard migraine treatment was 
not the same for all the RCTs and was 
based on physician choice. Routinely 
used medications included metoclo-
pramide (Reglan), ketorolac (Toradol), 
chlorpromazine (Compazine), and di-
phenhydramine (Benadryl). Doses of 
dexamethasone also varied, ranging 
from 8 to 24 mg; the median dose was 
15 mg. All studies cited the proportion 
of migraine patients who had self-re-
ported moderate to severe headache at 
24 to 72 hours after treatment. 
Dexamethasone prevents 1 recurrence 
in 10. The meta-analysis revealed a mod-
erate benefi t when dexamethasone was 
added to standard therapy for migraine 
headache in the ED. The addition of dexa-
methasone to standard migraine therapy 
prevented almost 1 in 10 patients from 
experiencing moderate to severe recur-
rent headache in 24 to 72 hours (relative 
risk [RR]=0.87, 95% confi dence interval 
[CI], 0.80-0.95). Transient side effects oc-
curred in about 25% of patients in both 
the treatment and placebo groups. 
Sensitivity analysis indicated that this 
meta-analysis was fairly robust, with no 
single trial dominating the results. There 
was no evidence of missing studies due to 
publication bias. These results are consis-
tent with a similar meta-analysis, which 
also included 7 studies, all but 1 of which 
were the same.5
WHAT’S NEW?
❚  Earlier ﬁ ndings gain
strength in numbers
This meta-analysis demonstrates that ad-
junctive therapy with a steroid is a viable 
option in the management of acute mi-
graines—an intervention that each of the 
individual 7 RCTs was too small to jus-
tify on its own. Specifi cally, the addition 
of dexamethasone to standard migraine 
treatment may prevent severe recurrent 
pain that would otherwise necessitate a 
repeat visit to the ED—or to your offi ce. 
CAVEATS
❚  Will it work in
an ofﬁ ce setting? 
This meta-analysis addresses more se-
vere headache recurrences, which are 
likely to lead patients to seek additional 
medication or repeat evaluation. Indeed, 
all 7 RCTs included in the evaluation 
were performed in an ED setting. And 
6 of the 7 trials assessed dexamethasone 
administered parenterally, which may 
not be possible in some offi ce settings. In 
the single trial in which the steroid was 
administered orally, patients were given 
8 mg dexamethasone in addition to intra-
venous phenothiazines. In the 63 patients 
included in that study, the relative risk of 
recurrent headache was 0.69 (95% CI, 
0.33-1.45). However, among those with 
a headache duration of <24 hours (n=40, 
63.5%), the relative risk was 0.33 (95% 
CI, 0.11-1.05).6
Other questions: It is not clear from 
this single trial whether oral dexametha-
sone is as effective as IV administration. 
The addition of 
dexamethasone to 
standard treatment 
may prevent severe 
recurrent pain that 
would otherwise 
necessitate an 
ofﬁ ce visit.
C O N T I N U E D
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Nor is it clear whether other cortico-
steroids will work as well, as no studies 
of other agents have been reported.1,5 The 
lowest effective dose of dexamethasone is 
also not known. 
BARRIERS TO IMPLEMENTATION
❚  Repeat steroid use raises 
risk of complications 
Based on this meta-analysis, it is unclear 
whether IV administration is required 
for the desired benefi t. Another potential 
concern is associated with the adminis-
tration of frequent dexamethasone bo-
luses in patients with frequent migraines, 
which could lead to any one of a num-
ber of steroid-related adverse reactions, 
including osteonecrosis.7 The risks of 
steroid-related complications should 
be considered in using this therapy, es-
pecially for patients receiving multiple 
doses of dexamethasone. ■
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